Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | -11.04% | -14.71% | -27.68% |
Mar. 11 | Biofrontera Files Prospectus for Potential Secondary Stock Offerings | MT |
Mar. 05 | Medicus Pharma Names COO | MT |
Sales 2021 | 28.79M 30.6M | Sales 2022 | 25.74M 27.36M | Capitalization | 97.31M 103M |
---|---|---|---|---|---|
Net income 2021 | 38M 40.39M | Net income 2022 | -44M -46.77M | EV / Sales 2021 | 2.79 x |
Net cash position 2021 | 3.61M 3.83M | Net cash position 2022 | 4.88M 5.18M | EV / Sales 2022 | 3.59 x |
P/E ratio 2021 |
2.18
x | P/E ratio 2022 |
-1.98
x | Employees | 92 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 32.4% |
Latest transcript on Biofrontera AG
1 day | -6.86% | ||
1 week | -4.12% | ||
Current month | -4.68% | ||
1 month | -8.94% | ||
3 months | -29.13% | ||
6 months | -37.31% | ||
Current year | -18.70% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 55 | 22-09-11 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 21-12-13 | |
Director/Board Member | - | 21-12-13 | |
Heikki Lanckriet
BRD | Director/Board Member | 47 | 21-12-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.29 | -11.04% | 41 448 |
24-04-18 | 0.326 | -6.86% | 8,794 |
24-04-17 | 0.35 | +2.94% | 8,794 |
24-04-16 | 0.34 | 0.00% | 1,500 |
24-04-15 | 0.34 | 0.00% | 56,410 |
Delayed Quote Xetra, April 18, 2024 at 11:35 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.70% | 22.18M | |
+27.97% | 672B | |
+23.58% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+2.96% | 211B | |
-0.41% | 203B | |
-10.02% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- B8F Stock